Swiss pharma giant Roche won approval from the Food and Drug Administration on Friday for an injectable version of its blockbuster multiple sclerosis therapy Ocrevus, cutting down the time needed ...

At the Roche Center for Catholic Education, we center the unique gifts and vocation of Catholic educators. Embedded within every program is a focus on the ‘cura personalis,’ or “care of the whole ...

Roche's Genentech division has formed an R&D partnership with Arsenal Biosciences focusing on developing and refining the biotech's programmable T cell-based therapies platform. Genentech is ...

Roche Holding AG said it isn’t concerned about side effects in a small study of a weight-loss shot, after details about the trial sent shares tumbling on Monday. “We’re not alarmed at all ...

Roche is reported to be considering the sale of its cancer data specialist Flatiron Health, just a few years after it bought the company for $1.9 billion. The Financial Times first revealed the ...

Ce rocher identifié par Perseverance fascine les scientifiques, car il présente une apparence jamais observée auparavant sur ...

Roche is holding out hopes that its injectable obesity prospect could eventually demonstrate 25% weight loss in late-stage trials, the pharma’s head of metabolism R&D has told Fierce Biotech.

Shares of Roche Holding AG fell after a poster highlighted side effects in an early-stage study of the Swiss pharmaceutical company’s experimental obesity medicine. The poster, released as part ...

FRANKFURT, Sept 11 (Reuters) - Roche (ROG.S), opens new tab said on Wednesday the promising results of an early-stage trial of its experimental weight-loss pill that bolstered its shares in July ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

ROCHE HOLDINGS AG : JP Morgan toujours à vendre sur le dossier 26/09 ZD ROCHE HOLDINGS AG : Goldman Sachs toujours à vendre sur le dossier 26/09 ZD ROCHE HOLDINGS AG : Berenberg n'est pas ...